Ertapenem and Faropenem against Mycobacterium tuberculosis: in vitro testing and comparison by macro and microdilution

Table 2 List of Mycobacterium tuberculosis isolates tested against ertapenem and faropenem

Strain	Phenotypical resistance profile	Meropenem clavulanate MIC (μg/ml)	Notes
03:013	S	32	MonoR
03:039	H	16	MonoR
04:018	H, R, clari, ethi	Failed	MDR
05:094	Fully susceptible	8
07:116	H, ethi	4	PolyR
11:136	S,H,R	> 32	MDR
11:156	S,H,R	4	MDR
11:191	H	16	MonoR
11:368	S,H,R	> 32	MDR
324	Fully susceptible	8
333	S,H,R	2	MDR
346	S,H,R	2	MDR
347	Fully susceptible	> 32
401	H,R	> 32	MDR
408	S, H, R	> 32	MDR
443	Fully susceptible	> 32
548	N/A*	> 32	XDR
421	S, H, R, EMB, CAP, Moxi	> 32	XDR
433	S, H, R, EMB, PYR, CAP, Moxi	8	XDR
H37Rv	Fully susceptible	2	Control reference strain

MDR Multi-Drug resistant; XDR Extensively drug resistance; MonoR Resistant to one drug only; PolyR Resistant to more than one drug other than H/R. The resistance profile is shown in the second column, with a variety of fully susceptible, MonoR, MDR and XDR samples (S Streptomycin, H Isoniazid, R Rifampicin, Clari Clarithromycin, Ethi Ethionamide, EMB Ethambutol, CAP=Capreomycin, Moxi = Moxifloxacin, PYR = Pyrazinamide). The MIC against Meropenem/clavulanate is also shown

ISSN: 1471-2180